PADI1 and Its Co-Expressed Gene Signature Unveil Colorectal Cancer Prognosis and Immunotherapy Efficacy

Figure 5

Survival analysis and prognostic performance of PCGs signature in colorectal cancer. (a) Kaplan–Meier analysis for overall survival in colorectal cancer between high- and low-risk patients in the training set (log-rank test, ). (b) Kaplan–Meier analysis for overall survival in colorectal cancer between high- and low-risk patients in the Kaplan–Meier analysis for overall survival in colorectal cancer between high- and low-risk patients in the internal validation set (log-rank test, ). (c) PCGs survival status in the training cohort of colorectal cancer patients. (d) PCGs survival status in the internal validation cohort of colorectal cancer patients. (e) PCGs risk scores in the training cohort of colorectal cancer patients. (e) PCGs risk scores in the internal validation cohort of colorectal cancer patients. (f) Receiver operating characteristic (ROC) curve survival at 1/3/5 years in the training set predicted by PCGs. (g) Receiver operating characteristic (ROC) curve survival at 1/3/5 years in the internal validation set predicted by PCGs. (h).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)